血液透析滤过对肾衰竭神经病变进展的影响:一项随机对照试验
FINESSE 研究为开放标签、盲法终点评估的随机对照试验,将维持性血液透析患者随机分配至血液透析滤过或高通量血液透析,随访48个月或至死亡/停止透析。主要结局为每年改良总神经病变评分较基线的平均变化。结果显示两组神经病变进展无显著差异,血液透析滤过未改善神经病变进展。
要点
- 血液透析滤过与高通量血液透析相比,未显著延缓神经病变进展。
- 两组生存率和不良事件发生率无差异。
- 神经病变在透析患者中仍常见,缺乏疾病修饰治疗。
核心结论
- 血液透析滤过未影响神经病变进展,与血液透析相比无显著差异。
研究设计与样本
- FINESSE 研究为开放标签、盲法终点评估的随机对照试验,纳入124例维持性血液透析患者,随机分配至血液透析滤过或高通量血液透析,随访48个月或至死亡或停止透析,平均随访41个月。
主要发现
- 基线时91例(73%)存在神经病变(改良总神经病变评分≥2),38例(31%)为中重度(评分9-28)。
- 血液透析滤过组对流剂量中位数为24.7(四分位距22.4-26.5)L。
- 改良总神经病变评分(均值±标准误)在血液透析滤过组和高通量血液透析组分别恶化1.7(0.4)/28和1.2(0.4)/28,平均差异0.5(95%置信区间-0.7至1.7;P=0.37)。
- 生存率无差异(风险比1.24;95%置信区间0.61至2.51;log rank P=0.55)。
- 按随访时间调整的不良事件数量无差异(相对风险1.05;95%置信区间0.83至1.32;P=0.68)。
临床怎么用
- 对于维持性血液透析患者,不应期望通过血液透析滤过来延缓神经病变进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Neuropathy is a common complication of kidney disease that lacks proven disease-modifying treatments. Hemodiafiltration improves clearance of uremic toxins and is associated with better nerve function than hemodialysis. We aimed to determine whether hemodiafiltration reduces the progression of neuropathy in people receiving hemodialysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE) study was an open-label, blinded end point assessment, controlled trial that randomized maintenance hemodialysis recipients to hemodiafiltration or high-flux hemodialysis for 48 months or until death or cessation of dialysis at four study centers. The primary outcome was the mean change in the yearly modified total neuropathy score from baseline, with time points weighted equally. RESULTS: A total of 124 participants were randomized and followed for a mean of 41 months. At baseline, neuropathy was present in 91 (73%) participants (modified total neuropathy score greater than or equal to two), and 38 (31%) had moderate to severe neuropathy (modified total neuropathy score 9-28). Convection volume in the hemodiafiltration arm was a median of 24.7 (interquartile range, 22.4-26.5) L. The mean modified total neuropathy score (SEM) worsened by 1.7 (0.4)/28 and 1.2 (0.4)/28 in the hemodiafiltration and hemodialysis groups, respectively, with a mean difference of 0.5 (95% confidence interval, -0.7 to 1.7; P=0.37). There was no difference in survival (hazard ratio, 1.24; 95% confidence interval, 0.61 to 2.51; log rank P=0.55) or any of the prespecified adverse events. There was no difference between groups in the number of participants who suffered an adverse event adjusted by follow-up time (relative risk, 1.05; 95% confidence interval, 0.83 to 1.32; P=0.68). CONCLUSIONS: Neuropathy is still a common complication of kidney disease without disease-altering therapy. Hemodiafiltration did not affect neuropathy progression compared with hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Filtration in the Neuropathy of End-Stage Kidney Disease Symptom Evolution (FINESSE), ACTRN12609000615280.
引用
- Kang A, Arnold R, Gallagher M, et al. Effect of Hemodiafiltration on the Progression of Neuropathy with Kidney Failure: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2021. PMID: 34233923. doi:10.2215/CJN.17151120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。